Showing 2881-2890 of 4091 results for "".
- New From InMode: Triton Multi-Wavelength Hair Removal Laserhttps://practicaldermatology.com/news/new-from-inmode-triton-multi-wavelength-hair-removal-laser/2457698/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company say
- New Data from DermTech Presented at International Investigational Dermatology Meetinghttps://practicaldermatology.com/news/new-data-from-dermtech-presented-at-international-investigational-dermatology-meeting/2457724/DermTech, Inc., has announced the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting
- New from Jergens: Nourishing Honey Dry Skin Moisturizerhttps://practicaldermatology.com/news/new-from-jergens-nourishing-honey-dry-skin-moisturizer/2457984/Jergens is launching their new Nourishing Honey Dry Skin Moisturizer. Formulated with antioxidant-packed Orange Blossom Honey, which is known to contain potent antibacterial and anti-inflammatory properties, the new Jergens® Nouri
- Sensus Healthcare Wins Technology Award from Greater Miami Chamber of Commercehttps://practicaldermatology.com/news/sensus-healthcare-wins-technology-award-from-greater-miami-chamber-of-commerce/2458174/Sensus Healthcare, Inc. was awarded the 2017 Technology Leader of the Year for the Disruptive Technology by The Greater Miami Chamber of Commerce. Sensus provides a non-invasive, cost-effective treatment for NMSC and keloids using the company’s proprietary,
- Positive Results Announced from SebuDerm Gel Study in Treatment of Seborrheic Dermatitishttps://practicaldermatology.com/news/positive-results-announced-from-sebuderm-gel-study-in-treatment-of-seborrheic-dermatitis/2458237/The results of a clinical study evaluating the impact of Sonoma Pharmaceuticals, Inc.'s SebuDerm (topical hypochlorous acid) gel in the treatment of mild to moderate facial and scalp seborrheic dermatitis were presented at the 13th Annual Maui Dermatology Conference in Maui, HI.
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- NEWA®, Home-Use RF Skin-Care System Launches From Eclipsehttps://practicaldermatology.com/news/newa-home-use-rf-skin-care-system-launches-from-eclipse/2458350/The DIY at-home beauty device market is exploding, and Eclipse Aesthetics®, LLC., in partnership with EndyMed Medical Ltd., is upping the ante with the
- Launches, Anniversaries and More: Aesthetic News from Around the Webhttps://practicaldermatology.com/news/launches-anniversaries-and-more-aesthetic-news-from-around-the-web/2458425/RealSelf Rolls Out RealSelf Business Pages RealSelf is launching of RealSelf Business Pages so doctors can showcase the full range of providers at a practice as well as the tr
- Mass Spectrometry Test Helps Distinguish Atypical Moles From Melanomahttps://practicaldermatology.com/news/mass-spectrometry-test-helps-distinguish-atypical-moles-from-melanoma/2458447/Mass spectrometry may aid in the diagnosis of atypical moles, new research suggests. In this study, mass spectrometry, which analyzes the level of proteins within mole cells, correlated better than the gold standard of histologic examination to determine if an atypical mole was benign or
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),